Prader-Willi Syndrome
Pipeline by Development Stage
Drug Modality Breakdown
Competitive Landscape
17 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 25 trials with date data
Clinical Trials (25)
Total enrollment: 1,600 patients across 25 trials
Tirzepatide in PWS, HO and GNSO
A Study of Pitolisant in Participants With Prader-Willi Syndrome
A Study of Pitolisant in Patients With Prader-Willi Syndrome
Open-Label Extension Study of DCCR in Patients With Prader-Willi Syndrome
Study of the Efficacy and Safety of Somatropin in Japanese Participants With PWS
An Open-Label Study of DCCR Tablet in Patients With PWS
Open-Label Extension Study of DCCR in PWS Followed by Double-Blind, Placebo-Controlled, Randomized Withdrawal Period
A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome
A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone Injection in Patients With Prader-Willi Syndrome
A Study of CSTI-500 in Patients With Prader-Willi Syndrome
A 2-Part Study to Assess Efficacy, Safety and Tolerability of BMB-101 for the Treatment of Patients With Prader-Willi Syndrome.
A Study of Setmelanotide in Patients With Prader-Willi Syndrome
An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001)
Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome
A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome
A Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension
Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome
A Pharmacokinetic and Safety Study of CSTI-500 in Subjects With Prader-Willi Syndrome
Observational Study of VYKAT™ XR in Patients With Prader-Willi Syndrome
Home-based SSP on Individuals With PWS
Effects of Exenatide on Overweight Adolescents With Prader-Willi Syndrome
Octreotide Therapy in Children and Young Adults With Prader-Willi Syndrome (PWS)
Characteristics of Prader-Willi Syndrome and Early-onset Morbid Obesity
Nordic Study on the Effects of Growth Hormone (Norditropin SimpleXx) Treatment in Adults With Prader-Willi Syndrome
Treatment of Self-Injurious Behavior in Individuals With Prader-Willi Syndrome
Related Jobs
Sr. Director, Brand Marketing
Pharmacovigilance Scientist
Director - National Accounts
Associate Director, Regulatory Affairs
Manager, Quality Systems & Administration
Human Resource Business Partner
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.